866-997-4948(US-Canada Toll Free)

Epithelial Ovarian Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Ovarian Cancer

No. of Pages : 106 Pages

 

Global Markets Directs, Epithelial Ovarian Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Epithelial Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer. Epithelial Ovarian Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Epithelial Ovarian Cancer.
  • A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Epithelial Ovarian Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Epithelial Ovarian Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Epithelial Ovarian Cancer 9
Epithelial Ovarian Cancer Therapeutics under Development by Companies 11
Epithelial Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Epithelial Ovarian Cancer Therapeutics Products under Development by Companies 17
Epithelial Ovarian Cancer Therapeutics Products under Investigation by Universities/Institutes 18
Companies Involved in Epithelial Ovarian Cancer Therapeutics Development 19
Boehringer Ingelheim GmbH 19
Amgen Inc. 20
AstraZeneca PLC 21
Oxford BioMedica plc 22
Novartis AG 23
Astellas Pharma Inc. 24
Bayer AG 25
Prima BioMed Limited 26
Synta Pharmaceuticals Corp. 27
Oasmia Pharmaceutical AB 28
TRION Pharma GmbH 29
BioNumerik Pharmaceuticals, Inc. 30
VentiRx Pharmaceuticals, Inc. 31
RECEPTA Biopharma S.A. 32
Epithelial Ovarian Cancer Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
trebananib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
sorafenib tosylate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
elesclomol - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
paclitaxel - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TroVax - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
MEK-162 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
nintedanib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
catumaxomab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CVac - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VTX-2337 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
levonorgestrel - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
plevitrexed - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
RebmAb-100 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
cositecan - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
EGEN-001 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NY-ESO-1 Overlapping Peptides Vaccine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
HER-2/Neu Specific T Cells - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MV-NIS Vaccine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Globo-H-GM2-sTn-TF-Tn-KLH Conjugate + [QS-21] - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
DCVAC/OvCa - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Epithelial Ovarian Cancer Therapeutics Drug Profile Updates 81
Epithelial Ovarian Cancer Therapeutics Discontinued Products 97
Epithelial Ovarian Cancer Therapeutics - Dormant Products 98
Epithelial Ovarian Cancer Product Development Milestones 99
Featured News & Press Releases 99
Jul 03, 2013: Prima BioMed Activates Study Sites in Germany and Multiple European Countries for CANVAS Clinical Trial 99
Jun 01, 2013: GSKs Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer 99
Apr 17, 2013: Prima Biomed Receives Japanese Patent For CVac 100
Apr 10, 2013: MEI Pharma Presents Data On Mitochondrial Inhibitor Drug Candidate ME-344 At AACR Annual Meeting 2013 100
Mar 19, 2013: Prima BioMed Receives 3.8m Grant From Saxony Development Bank To Support Development Of CVac 100
Feb 27, 2013: Prima Biomed Commences Phase II/III Clinical Trial Of CVac In Europe 101
Feb 04, 2013: Prima BioMed To Present Data On R&D Of CVac At ISCT Annual Meeting 102
Jan 10, 2013: Morphotek Announces Top-Line Results Of Phase III Study Of Farletuzumab In Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer 102
Nov 14, 2012: Prima BioMed Releases Interim Immune Monitoring Data From CVac Phase II Clinical Trial 103
Oct 15, 2012: Prima BioMed Announces Positive Interim Data From CAN-003 Trial Of CVac For Ovarian Cancer 103


Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Table


Number of Products Under Development for Epithelial Ovarian Cancer, H2 2013 9
Products under Development for Epithelial Ovarian Cancer Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 18
Boehringer Ingelheim GmbH, H2 2013 19
Amgen Inc., H2 2013 20
AstraZeneca PLC, H2 2013 21
Oxford BioMedica plc, H2 2013 22
Novartis AG, H2 2013 23
Bayer AG, H2 2013 25
Prima BioMed Limited, H2 2013 26
Synta Pharmaceuticals Corp., H2 2013 27
Oasmia Pharmaceutical AB, H2 2013 28
TRION Pharma GmbH, H2 2013 29
BioNumerik Pharmaceuticals, Inc., H2 2013 30
VentiRx Pharmaceuticals, Inc., H2 2013 31
RECEPTA Biopharma S.A., H2 2013 32
Assessment by Monotherapy Products, H2 2013 33
Assessment by Combination Products, H2 2013 34
Assessment by Stage and Route of Administration, H2 2013 36
Assessment by Stage and Molecule Type, H2 2013 38
Epithelial Ovarian Cancer Therapeutics Drug Profile Updates 81
Epithelial Ovarian Cancer Therapeutics Discontinued Products 97
Epithelial Ovarian Cancer Therapeutics Dormant Products 98

List of Chart


Number of Products under Development for Epithelial Ovarian Cancer, H2 2013 9
Products under Development for Epithelial Ovarian Cancer Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 33
Assessment by Combination Products, H2 2013 34
Assessment by Route of Administration, H2 2013 35
Assessment by Stage and Route of Administration, H2 2013 36
Assessment by Molecule Type, H2 2013 37
Assessment by Stage and Molecule Type, H2 2013 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *